TORONTO, May 15, 2024 /PRNewswire/ -- AmacaThera Inc, a
clinical stage biotechnology company specializing in the
development of advanced sustained release hydrogel formulations,
has dosed its first human subject with AMT-143, the company's lead
asset in non-opioid acute pain management.
AMT-143 is a local slow-release non-opioid local anesthetic that
would leverage the AmacaGel platform to provide long-acting
post-operative pain relief and is the first therapeutic product
formulated to be delivered via AmacaGel, the Company's patented
technology platform.
Previously, the Company had tested the AmacaGel platform without
any active pharmaceutical agent. This trial will test the
platform combined with a known anesthetic. The study will
assess the tolerability, safety, pharmacokinetic and clinical
activity of the AmacaGel platform with a known compound that has a
long history of safety and efficacy.
If approved, AMT-143 could one day be used to reduce
post-operative pain without the need for opioids. AMT-143 would be
applied in the incisional site at the time of surgery to control
local pain.
"A successful outcome will be data demonstrating safety of our
asset, and release kinetics showing a sustained release longer than
the competitive products," said Dr. Mike
Cooke, Chief Executive Officer, and Co-Founder of
AmacaThera, "There is a real need for products that provide longer
relief than those currently available on the market."
Dr. Molly Shoichet is the
Company's Chief Scientific Officer and Co-Founder of AmacaThera.
The original technology was developed in her laboratory at the
University of Toronto. "My laboratory
has demonstrated compatibility of AmacaGel with a wide range of
therapeutics – from cells to biologics," said Shoichet, "With this
study, our goal is to provide human data on our technology that
will help advance AMT-143 to the clinic. At the same time, we are
building out the platform technology so that it can be leveraged
for other local-release therapeutics."
About AmacaThera
AmacaThera is a clinical stage biotechnology company
specializing in the development of advanced sustained release
hydrogel formulations to solve key therapeutics delivery challenges
with both off-patent and proprietary payloads. AmacaThera is
focused on developing an internal pipeline of pain management and
oncology assets; and partnering to solve key delivery challenges
with advanced proprietary therapeutic modalities.
AmacaThera's platform technology, AmacaGel, is a fast-gelling
physical hydrogel blend of two well-established medical-grade
polymers. It has been designed to liquify under shear force
to be delivered by a conventional syringe, rapidly forming a depot
at the injection site as it warms to body temperature. AMT-143, the
platform's lead asset, is a slow-release non-opioid local
anesthetic that leverages the AmacaGel platform to provide
long-acting post-operative pain relief.
For more information, visit www.amacathera.ca
Media Contact: Abhaya Khulbe,
Investor Relations, info@amacathera.ca
Logo -
https://mma.prnewswire.com/media/2412859/AmacaThera_Inc__AmacaThera_doses_First_In_Human_Study_to_Evaluat.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/amacathera-doses-first-in-human-study-to-evaluate-amt-143-for-non-opioid-treatment-of-post-operative-pain-302145665.html